Results 251 to 260 of about 60,209 (283)
Lymphangioleiomyomatosis Treatment With Sirolimus [PDF]
Archivos de Bronconeumología (English Edition), 2011 Lymphangioleiomyomatosis (LAM) is a rare lung disease, that predominantly affects young females and generally progresses to respiratory failure. There is not sufficient evidence to support the routine use of any treatment in LAM. The only treatment for severe LAM is currently lung transplantation.
Manuel Barrón +5 more
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Molecular actions of sirolimus: sirolimus and mTor
Transplantation Proceedings, 2003Recent therapeutic strategies to combat organ allograft rejection have focused on T-cell signaling pathways and the molecules that comprise them. The macrolide antibiotic produced by the bacterium Streptomyces hygroscopicus, known as sirolimus or rapamycin, has shown great therapeutic potential in the transplant setting.
Robert A. Kirken, Y.L Wang
openaire +3 more sources
Is Sirolimus Responsible for Proteinuria?
Transplantation Proceedings, 2004Sirolimus (SRL) is suspected to induce proteinuria. We retrospectively studied proteinuria in a population of liver (n = 29) and kidney transplant (n = 30) recipients switched to SRL with progressive diminution or withdrawal of calcineurin inhibitors (CNI).
P. Wolf +7 more
openaire +4 more sources
Clinical Pharmacokinetics of Sirolimus
Clinical Pharmacokinetics, 2001Sirolimus (previously known as rapamycin), a macrocyclic lactone, is a potent immunosuppressive agent. Sirolimus was recently approved by the US Food and Drug Administration, on the basis of 2 large, double-blind, prospective clinical trials, for use in kidney transplant recipients at a fixed dosage of 2 or 5 mg/day in addition to full dosages of ...
Barry D. Kahan, Kamran Mahalati
openaire +2 more sources
Durability of Sirolimus for Lymphangioleiomyomatosis
The American Journal of the Medical Sciences, 2017Lymphangioleiomyomatosis (LAM), a rare, multisystem disorder primarily affecting women of reproductive age, is characterized by cystic-appearing lung lesions, progressive loss of lung function, chylous effusions and renal angiomyolipomas. Sirolimus, an mammalian target of rapamycin inhibitor, has been shown to stabilize lung function, reduce symptoms ...
Alexandra Martirossian +4 more
openaire +3 more sources
Transplantation Proceedings, 2006
The mTOR inhibitor sirolimus improves renal transplant function compared with the nephrotoxic calcineurin inhibitors. We evaluated retrospectively the adverse events in 119 of 134 patients getting sirolimus which seemed to be caused by sirolimus. Patients were converted to sirolimus because of malignancies (n = 47), a creeping creatinine (n = 33), or ...
Michael Mengel +4 more
openaire +3 more sources
The mTOR inhibitor sirolimus improves renal transplant function compared with the nephrotoxic calcineurin inhibitors. We evaluated retrospectively the adverse events in 119 of 134 patients getting sirolimus which seemed to be caused by sirolimus. Patients were converted to sirolimus because of malignancies (n = 47), a creeping creatinine (n = 33), or ...
Michael Mengel +4 more
openaire +3 more sources
Rapamycin (sirolimus, rapamune)
Current Opinion in Nephrology and Hypertension, 1995Rapamycin is a novel immunosuppressive agent that is undergoing clinical trials for use in allograft rejection therapy. This paper reviews its in-vitro biological properties, the current state of knowledge concerning its mechanism of action, and its therapeutic applications.
Suren N. Sehgal +3 more
openaire +3 more sources
Sirolimus for Kaposi’s Sarcoma
The Journal of Heart and Lung Transplantation, 2006The risk of Kaposi's sarcoma (KS) is increased after organ transplantation. Management of KS in the cardiac transplant population may be difficult because reduction of immunosuppression is often not practical. This report describes a case of KS occurring in the early post-transplant period.
H. Arthur Coverdale +4 more
openaire +2 more sources
Radioreceptor assay for sirolimus
Clinical Biochemistry, 1996To develop a radioreceptor assay (RRA) for sirolimus (rapamycin, RAPA).A direct methanol extraction was used to prepare 45 patient samples for the RRA. Results were compared to the results obtained previously using high-performance liquid chromatography (HPLC).
Barry D. Kahan +7 more
openaire +3 more sources